in vivo
Flagship’s Sail Biomedicines announces second round of layoffs in 2025
Sail Biomedicines; Flagship Pioneering; layoffs; immunology pipeline; endless RNA; eRNA; in vivo CAR-T; biotech workforce reduction
AstraZeneca deepens cell therapy expansion with $1B EsoBiotec buyout
AstraZeneca, EsoBiotec, cell therapy, acquisition, ENaBL platform, in vivo cell engineering, oncology, autoimmune diseases